tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales

TG Therapeutics Boosts Revenue Forecast Amid Strong BRIUMVI Sales

TG Therapeutics ( (TGTX) ) has released its Q2 earnings. Here is a breakdown of the information TG Therapeutics presented to its investors.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

TG Therapeutics is a biopharmaceutical company focused on developing and commercializing novel treatments for B-cell diseases, with a particular emphasis on therapies for multiple sclerosis (MS). The company is known for its innovative approach in the healthcare sector, particularly with its flagship product BRIUMVI, an anti-CD20 monoclonal antibody therapy.

In its latest earnings report, TG Therapeutics announced a significant increase in revenue for the second quarter of 2025, driven primarily by the strong performance of BRIUMVI in the U.S. market. The company has raised its full-year revenue guidance for BRIUMVI, reflecting its confidence in the product’s market potential and ongoing growth.

Key financial highlights include a total revenue of $141.1 million for the second quarter, with BRIUMVI contributing $138.8 million, marking a 91% growth compared to the same period last year. The company also reported a net income of $28.2 million for the quarter, a substantial increase from the previous year’s $6.9 million. Additionally, TG Therapeutics has expanded BRIUMVI’s commercialization internationally, with approvals in the EU, UK, Switzerland, and Australia.

The company is actively pursuing further development of BRIUMVI, including a subcutaneous formulation and a consolidated dosing regimen, which are currently under study. These advancements are expected to enhance BRIUMVI’s market position and redefine treatment expectations for MS patients.

Looking ahead, TG Therapeutics remains optimistic about its growth trajectory, supported by strong physician confidence and patient experiences with BRIUMVI. The company anticipates that its strategic initiatives and ongoing clinical trials will continue to drive revenue growth and solidify its position in the biopharmaceutical market.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1